Alexander Olawaiye
Gynecologic Oncology · Pittsburgh, PANPI 1811987183
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $163,567 of the $226,117 with a category attached, or 72.3%. It is spread thinly across 31 manufacturers, the largest accounting for just 21.8%. Among gynecologic oncology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $646.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$49K
- AstraZeneca$43K
- GSK$27K
- Merck$19K
- Intuitive Surgical$19K
- Daiichi Sankyo Inc.$11K
- plus $58K from 25 others
Across 230 payments — averaging $16,649 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.2M
- Corcept Therapeutics$652K
- AstraZeneca$418K
- Pfizer$409K
- Tesaro, Inc.$327K
- Seagen Inc.$235K
- plus $621K from 9 others
What the payments were for
- Consulting fees$163,56772%
- Speaking & faculty fees$11,0105%
- Travel & lodging$15,0557%
- Food & beverage$19,3609%
- Education$17,1268%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 27 | $49,249 |
| AstraZeneca | 86 | $43,173 |
| GSK | 29 | $26,988 |
| Merck | 25 | $19,279 |
| Intuitive Surgical | 19 | $18,627 |
| Daiichi Sankyo Inc. | 16 | $11,023 |
| Eisai Inc. | 21 | $10,890 |
| Tesaro, Inc. | 15 | $10,754 |
| Clovis Oncology, Inc. | 43 | $9,025 |
| Biom'up SA | 13 | $6,914 |
| AbbVie | 6 | $4,520 |
| Dova Pharmaceuticals | 7 | $3,724 |
| Aadi Bioscience, Inc. | 5 | $3,100 |
| Novocure GmbH | 1 | $2,400 |
| Genentech, Inc. | 1 | $2,200 |
| Genentech USA, Inc. | 2 | $1,185 |
| Seagen Inc. | 4 | $492 |
| R-pharm US LLC | 3 | $434 |
| Myriad Genetic Laboratories, Inc. | 3 | $432 |
| Novocure Inc. | 7 | $313 |
| Karyopharm Therapeutics Inc. | 3 | $284 |
| Genmab U.S., Inc. | 3 | $202 |
| Pfizer | 2 | $172 |
| Eagle Pharmaceuticals, Inc. | 1 | $149 |
| Gilead | 1 | $124 |
| Immunogen, Inc. | 1 | $119 |
| Bayer | 1 | $101 |
| Amgen | 2 | $100 |
| Puma Biotechnology, Inc. | 1 | $60 |
| Eli Lilly | 1 | $53 |
| Johnson & Johnson | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$226,117 in reported general payments places this provider in the 90th percentile of 90 gynecologic oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 11 | $201,392 |
| Dexamethasone | 17 | $621 |
| Prochlorperazine Maleate | 27 | $570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $26,988 | $201,39211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 90 gynecologic oncology providers in Pennsylvania.
Other gynecologic oncology in Pittsburgh
- Thomas KrivakPittsburgh$1.6M
- John NakayamaPittsburgh$194K
- Sarah CraftonPittsburgh$46K
- Eirwen MillerPittsburgh$27K
- Jessica BergerPittsburgh$4K
- Madeleine Courtney-BrooksPittsburgh$2K
- Alison GarrettPittsburgh$2K
- Christopher MorsePittsburgh$2K
- Mackenzy RadolecPittsburgh$1K
- Eileen SegretiPittsburgh$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.